Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Harvard Bioscience

Start price
Target price
Perf. (%)
€6.50
27.07.21
-
27.07.22
-25.54%
02.03.22

Atossa Genetics Inc

Start price
Target price
Perf. (%)
€3.50
26.07.21
-
26.07.22
-74.03%
27.07.22

Probably not worthwhile Investment
Ardelyx Inc.

Start price
Target price
Perf. (%)
€1.32
26.07.21
-
26.07.22
-48.82%
27.07.22

Risky Investment
buy
Dynatronics Corp

Start price
Target price
Perf. (%)
€1.07
26.07.21
€2.50
26.07.22
-1.87%
07.08.21

Could be worthwhile Investment >10% per year
Capable Management
Good culture
Few uniques
buy
Trinity Biotech ADR

Start price
Target price
Perf. (%)
€1.66
26.07.21
-
26.07.22
-21.08%
27.07.22

Could be very worthwhile Investment >20% year
buy
Sartorius AG ST

Start price
Target price
Perf. (%)
€480.00
25.07.21
€550.00
25.07.22
-18.33%
25.07.22

buy
Castlight Healt.b

Start price
Target price
Perf. (%)
€1.85
23.07.21
-
23.07.22
-4.32%
02.03.22

buy
Valneva SE

Start price
Target price
Perf. (%)
€11.24
20.07.21
€20.00
20.07.22
116.90%
25.11.21

Could be worthwhile Investment >10% per year
Very valuable balance sheet
buy
Stratec SE

Start price
Target price
Perf. (%)
€121.80
20.07.21
€135.00
20.07.22
4.76%
30.07.21

Risky Investment
buy
Trupanion Inc.

Start price
Target price
Perf. (%)
€87.08
18.07.21
-
18.07.22
-27.35%
18.07.22

buy
Sartorius AG ST

Start price
Target price
Perf. (%)
€474.50
15.07.21
-
15.07.22
-30.56%
13.03.22

buy
Paul Hartmann AG

Start price
Target price
Perf. (%)
€360.00
14.07.21
€450.00
14.07.22
0.28%
24.07.21

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
Standard Investments for future growth
buy
Seelos Therapeutics Inc.

Start price
Target price
Perf. (%)
€2.02
14.07.21
-
14.07.22
-24.07%
05.12.21

buy
Allied Healthcare Products Inc

Start price
Target price
Perf. (%)
€5.75
14.07.21
-
14.07.22
-68.30%
15.07.22

Could be worthwhile Investment >10% per year
buy
Chemocentryx Inc.

Start price
Target price
Perf. (%)
€14.10
13.07.21
€21.00
13.07.22
-10.78%
13.08.21

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
buy
Perrigo Co. plc

Start price
Target price
Perf. (%)
€39.00
13.07.21
-
13.07.22
-18.36%
02.05.22

Could be worthwhile Investment >10% per year
Undervalued
Higher risks for its business
buy
Ryman Healthcare Group Ltd.

Start price
Target price
Perf. (%)
€7.98
13.07.21
€10.00
13.07.22
-31.03%
13.07.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Fair valuation
Capable Management
Chemocentryx Inc.

Start price
Target price
Perf. (%)
€13.66
13.07.21
-
13.07.22
69.13%
14.07.22

Could be worthwhile Investment >10% per year
Standard Investments for future growth
Sustainability is important
High valuation
buy
Biolife Solutions Inc

Start price
Target price
Perf. (%)
€40.84
13.07.21
-
13.07.22
-62.81%
13.07.22

buy
Medtronic plc

Start price
Target price
Perf. (%)
€108.20
12.07.21
-
12.07.24
-28.34%
11.03.24

Could be worthwhile Investment >10% per year
buy
Teladoc Health Inc

Start price
Target price
Perf. (%)
€132.45
12.07.21
-
12.07.22
-61.65%
13.03.22

buy
Catalyst Pharmaceutical Partners Inc

Start price
Target price
Perf. (%)
€4.66
12.07.21
-
12.07.22
48.95%
13.03.22

buy
Sernova Corp.

Start price
Target price
Perf. (%)
€0.94
12.07.21
-
12.07.22
5.94%
13.03.22

buy
Alpha Pro Tech Ltd.

Start price
Target price
Perf. (%)
€6.22
11.07.21
€12.00
11.07.22
-30.03%
12.07.22

Could be worthwhile Investment >10% per year
Differentiated customer and product portfolio
Small cyclical dependencies
Undervalued
Inovio Pharma

Start price
Target price
Perf. (%)
€6.92
10.07.21
€5.80
10.07.22
-6.86%
27.11.21

Very low/no dividend yield expected
Risky balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital